Core platform patent for Roche Brain Shuttle (BrainShuttle): monovalent single-chain Fab against TfR1 fused to therapeutic IgG; monovalent format prevents lysosomal sorting, enabling 55-fold increase in brain Aβ engagement versus parent antibody.

Evidence span

Core platform patent for Roche Brain Shuttle (BrainShuttle): monovalent single-chain Fab against TfR1 fused to therapeutic IgG; monovalent format prevents lysosomal sorting, enabling 55-fold increase in brain Aβ engagement versus parent antibody.

From reviewer:will-blair-bot

Method & conditions

Evidence type

observational

Method

manual state transition

Conditions

Three-component architecture: brain effector entity (e.g., anti-Aβ IgG) + monovalent TfR1-binding entity + peptide linker; monovalency is mechanistically essential for transcytosis over lysosomal trapping; pharmaceutical compositions and methods for neurodegenerative disease treatment.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required